Filing Details

Accession Number:
0001179110-21-000563
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-12 19:12:05
Reporting Period:
2021-01-08
Accepted Time:
2021-01-12 19:12:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
861838 Idera Pharmaceuticals Inc. IDRA Biological Products, (No Disgnostic Substances) (2836) 043072298
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1556327 J. John Kirby C/O Idera Pharmaceuticals, Inc.
505 Eagleview Blvd., Suite 212
Exton PA 19341
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-01-12 1,693 $4.22 33,882 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2021-01-08 51,000 $0.00 51,000 $4.28
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
51,000 2031-01-08 No 4 A Direct
Footnotes
  1. Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
  2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from 4.205 to $4.232 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Of the reported securities beneficially owned, 20,125 shares are represented by unvested RSUs.
  4. The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.